ERNA vs. KZIA, GRI, ADIL, ALZN, TRIB, GNPX, EVOK, AEZS, VINC, and EDSA
Should you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Kazia Therapeutics (KZIA), GRI Bio (GRI), Adial Pharmaceuticals (ADIL), Alzamend Neuro (ALZN), Trinity Biotech (TRIB), Genprex (GNPX), Evoke Pharma (EVOK), Aeterna Zentaris (AEZS), Vincerx Pharma (VINC), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry.
Eterna Therapeutics vs.
Kazia Therapeutics (NASDAQ:KZIA) and Eterna Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.
Kazia Therapeutics currently has a consensus price target of $20.00, suggesting a potential upside of 1,288.89%. Given Kazia Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Kazia Therapeutics is more favorable than Eterna Therapeutics.
30.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 70.6% of Eterna Therapeutics shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 4.5% of Eterna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Kazia Therapeutics has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%.
Kazia Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, Eterna Therapeutics has a beta of 4.29, indicating that its stock price is 329% more volatile than the S&P 500.
Kazia Therapeutics has higher revenue and earnings than Eterna Therapeutics.
In the previous week, Kazia Therapeutics' average media sentiment score of 0.00 beat Eterna Therapeutics' score of -0.26 indicating that Kazia Therapeutics is being referred to more favorably in the media.
Kazia Therapeutics received 79 more outperform votes than Eterna Therapeutics when rated by MarketBeat users.
Summary
Kazia Therapeutics beats Eterna Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Eterna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Eterna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ERNA) was last updated on 1/22/2025 by MarketBeat.com Staff